John
Amory
MD
MPH
MSc
Education & Training
- MD, University of California, San Francisco, CA (1989–1994)
- Residency in Internal Medicine, University of California, San Francisco, CA (1994–1997)
- MPH, University of Washington, Seattle, WA (2004–2006)
- MSc, University of Washington, Seattle, WA (2017)
Honors
- Elected Member, American Society of Clinical Investigation (2013)
- Young Andrologist Award (2007)
- Helen and Phillip Fialkow Scholar (2004)
- Fellowship, American College of Physicians (2003)
- Alpha Omega Alpha, Honorary Inductee (2003)
- Paul Beeson Award for Excellence in Housestaff Instruction (2003)
- Weingarten Memorial Award for Outstanding Third-Year Medicine Resident (1997)
- Martin Memorial Award for Outstanding Second-Year Medicine Resident (1996)
- Dean's Prize for Medical Student Research (1992)
Research
Dr. Amory’s principal area of research is in male reproductive health, specifically focused on the areas of male contraception, male infertility, and the treatment of hypogonadism. He was elected to membership in the American Society of Clinical Investigation in 2013. Currently, he serves as the Associate Editor of Andrology and as a member of the NIH’s study section on cellular and molecular reproduction.
RETINOIC ACID IN MALE INFERTILITY
The major goal of this grant is to determine the impact of treating men with infertility with 13-cis-retinoic acid.
INHIBITION OF TESTICULAR RETINOIC ACID BIOSYNTHESIS FOR MALE CONTRACEPTION
The goal of this project is to develop safe, effective contraceptive for men based on the inhibition of testicular retinoic acid biosynthesis by novel drugs.
DEVELOPMENT OF ORAL ANDROGENS
The goal of this project is to develop safe and effective methods of oral testosterone therapy for men with hypogonadism.
Research Interests
- Male contraception
- Androgens in aging
- Testosterone deficiency
- Klinefelter's Syndrome
- Male infertility
Publication highlights
- Amory JK, Wang C, Swerdloff R, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. Journal of Clinical Endocrinology and Metabolism 2007; 92:1659–1665.
- Amory JK, Muller CH, Shimshoni AJ, Isoherranen N, Paik J, Moreb JS, Amory DW, Evanoff R, Goldstein AS, Griswold MD. Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. Journal of Andrology 2011; 32(1):111–119. PMCID: PMC3370679.
- Nya-Ngatchou JJ, Arnold SLM, Walsh TJ, Muller CH, Page ST, Isoherranen N, Amory JK. Intratesticular 13-cis Retinoic Acid is Reduced in Men with Abnormal Semen Analyses. Andrology 2013 March; 1: 325–331. PMCID: PMC3578657.
- Amory JK, Arnold S, Walsh T, Lardone MC, Piottante A, Ebensperger MD, Isoherraenen N, Muller CH, Castro A. Levels of the Retinoic Acid Synthesizing Enzyme ALDH1A2 are Lower in Testicular Tissue from Men with Infertility. Fertility and Sterility 2014 Apr;101(4):960–966. PMCID:PMC3972330.
- Paik J, Haenisch M, Muller CH, Goldstein AS, Arnold S, Isoherranen H, Brabb T, Treuting PM, Amory JK. Inhibition of Retinoic Acid Biosynthesis by WIN 18,446 Markedly Suppresses Spermatogenesis and alters Retinoid Metabolism in Mice. Journal of Biological Chemistry 2014 May 23;289(21):15104–17. PMCID: PMC4031560.
- Amory JK, Ostrowski KA, Gannon JR, Berkseth K, Stevison F, Isoherranen N, Muller CH, Walsh T. Isotretinoin administration improves sperm production in some men with infertility from oligoasthenozoospermia: A Pilot Study. Andrology 2017 5:1115–1123.
- Chen Y, Zhu J, Ho Hong K, Georg G, Goldstein AS, Amory JK, Schonbrunn E. Structural basis of ALDH1A2 inhibition by irreversible and reversible small molecule inhibitors. ACS Chemical Biology 2018 Mar 16;13(3):582–590.